Scotia and Laserscope seek laser cancer therapy clearance
This article was originally published in Clinica
Executive Summary
UK-based Scotia Holdings has applied for approval from the US FDA to market Laserscope's photodynamic laser systems as part of its new drug application (NDA) for the light-sensitive anti-cancer drug Foscan.